Publication | Open Access
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
118
Citations
30
References
2020
Year
These findings support the clinical testing of DT2216 in patients with Bcl-xL-dependent TCLs, both as a single agent and in rational combinations.
| Year | Citations | |
|---|---|---|
Page 1
Page 1